Core Viewpoint - Heng Rui Medicine's subsidiary has received approval for clinical trials of HRS9531 injection, a novel dual agonist targeting GIPR and GLP-1R, aimed at improving blood sugar levels and reducing weight [1] Group 1: Company Developments - Heng Rui Medicine (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice from the National Medical Products Administration [1] - The clinical trials for HRS9531 injection will commence shortly [1] Group 2: Product Details - HRS9531 injection is a new oral dual agonist with global intellectual property rights, targeting gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) [1] - The drug is designed to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity, thereby improving blood sugar levels and aiding in weight loss [1] Group 3: Financial Investment - The cumulative research and development investment for the HRS9531 project has reached approximately 256 million yuan [1]